Allogeneic haematopoietic cell transplantation for myelofibrosis: a real‐life perspective-Reference-Cited by-同舟云学术

Allogeneic haematopoietic cell transplantation for myelofibrosis: a real‐life perspective

Published:2021-04-21 Issue:4 Volume:195 Page:495-506
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Savani Malvi¹^ORCID,Dulery Rémy²^ORCID,Bazarbachi Abdul Hamid²³^ORCID,Mohty Razan²⁴,Brissot Eolia²,Malard Florent²^ORCID,Bazarbachi Ali⁴,Nagler Arnon⁵,Mohty Mohamad²^ORCID

Affiliation:

1. Division of Hematology and Oncology University of Arizona Cancer Center Tucson AZ USA

2. Service d’Hématologie Clinique et Thérapie Cellulaire Hôpital Saint‐Antoine Sorbonne Université INSERM UMRs 938 Paris France

3. Department of Internal Medicine Jacobi Medical Center Albert Einstein College of Medicine New York New York USA

4. Department of Internal Medicine Bone Marrow Transplantation Program American University of Beirut Medical Center Beirut Lebanon

5. Hematology Division Chaim Sheba Medical Center Tel‐Hashomer Ramat Gan Israel

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17469

Reference75 articles.

1. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

2. Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

3. Myelofibrosis in 2019: moving beyond JAK2 inhibition

4. How I treat myelofibrosis after failure of JAK inhibitors

5. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis;Annals of Hematology;2024-03-18

3. STAT5a and SH2B3 novel mutations display malignancy roles in a triple-negative primary myelofibrosis patient;Cancer Gene Therapy;2023-12-22

4. How I treat transplant-eligible patients with myelofibrosis;Blood;2023-11-16

5. The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH);Leukemia;2022-04-16